1. External application of NF-κB inhibitor DHMEQ suppresses development of atopic dermatitis-like lesions induced with DNCB/OX in BALB/c mice.
- Author
-
Jiang X, Lan Y, Wei B, Dai C, Gu Y, Ma J, Liu X, Umezawa K, and Zhang Y
- Subjects
- Animals, Cytokines immunology, Mice, Mice, Inbred BALB C, NF-kappa B immunology, Ointments, Benzamides pharmacology, Cyclohexanones pharmacology, Dermatitis, Atopic chemically induced, Dermatitis, Atopic drug therapy, Dermatitis, Atopic immunology, Dermatitis, Atopic pathology, Dinitrochlorobenzene toxicity, Epidermis immunology, Epidermis pathology, NF-kappa B antagonists & inhibitors, Oxazolone toxicity
- Abstract
Context: Dehydroxymethylepoxyquinomicin (DHMEQ) which is originally developed as an analog of antibiotic epoxyquinomicin C is a specific and potent inhibitor of NF-κB and has been shown to possess promising potential as an anti-inflammatory and anti-tumor agent., Objective: This study examines DHMEQ's effect on therapeutic potential for atopic dermatitis (AD)-like lesions., Materials and Methods: AD lesions were chronically induced by the repetitive and alternative application of 2,4-dinitrochlorobenzene (DNCB) and oxazolone (OX) on ears in BALB/c mice. The mice were then externally treated with DHMEQ ointment. Macroscopic and microscopic changes of the skin lesions were observed and recorded., Results: DHMEQ inhibited ear swelling and relieved clinical symptoms of the AD-like lesions induced by DNCB/OX in BALB/c mice. Histopathology examination illustrated that it significantly decreased DNCB/OX-induced epidermal thickness, the infiltration of inflammatory cells, and the count of mast cell. The elevated level of immunoglobulin E (IgE) in serum and the mRNA levels of interferon γ (IFN-γ), interleukin 4 (IL-4) and IL-13 in the ear tissues, were also suppressed by DHMEQ., Discussion and Conclusion: This study indicated that DHMEQ would be useful for the treatment of AD.
- Published
- 2017
- Full Text
- View/download PDF